OTCMKTS:PARD - Poniard Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0510 0.00 (0.00 %)
(As of 10/23/2018 04:00 PM ET)
Previous Close$0.0510
Today's Range$0.0510 - $0.0510
52-Week Range$0.0430 - $0.13
VolumeN/A
Average Volume84 shs
Market Capitalization$80,000.00
P/E RatioN/A
Dividend YieldN/A
Beta0.91
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Receive PARD News and Ratings via Email

Sign-up to receive the latest news and ratings for PARD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PARD
Previous Symbol
CUSIPN/A
Phone206-286-2501

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares1,500,000
Market Cap$80,000.00
OptionableN/A

Poniard Pharmaceuticals (OTCMKTS:PARD) Frequently Asked Questions

What is Poniard Pharmaceuticals' stock symbol?

Poniard Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PARD."

Who are some of Poniard Pharmaceuticals' key competitors?

Who are Poniard Pharmaceuticals' key executives?

Poniard Pharmaceuticals' management team includes the folowing people:
  • Dr. Paul G. Abrams, Exec. Officer

How do I buy shares of Poniard Pharmaceuticals?

Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Poniard Pharmaceuticals' stock price today?

One share of PARD stock can currently be purchased for approximately $0.0510.

How big of a company is Poniard Pharmaceuticals?

Poniard Pharmaceuticals has a market capitalization of $80,000.00.

What is Poniard Pharmaceuticals' official website?

The official website for Poniard Pharmaceuticals is http://www.poniard.com.

How can I contact Poniard Pharmaceuticals?

Poniard Pharmaceuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]


MarketBeat Community Rating for Poniard Pharmaceuticals (OTCMKTS PARD)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaceuticals and other stocks. Vote "Outperform" if you believe PARD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PARD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel